How Much Nattokinase Per Day: Dosage by Research

Most clinical trials on nattokinase have used daily doses in the range of 2,000 to 10,800 fibrinolytic units (FU), with 2,000 FU per day being the single most commonly studied amount. There is no officially established dose from any major regulatory agency, so the best guidance comes from the research itself, which has tested doses as low as 1,200 FU and as high as 13,000 FU per day for various cardiovascular outcomes. The range matters because different doses have been linked to different effects, and the units on supplement labels can be confusing.

What Doses Have Clinical Trials Actually Used

The research on nattokinase spans a surprisingly wide dosing spectrum. Across published trials focused on thrombosis prevention and cardiovascular markers, daily doses have included 1,200 FU, 2,000 FU, 3,000 FU, 4,000 FU, 6,000 FU, 7,000 FU, and even 13,000 FU.¹ That is a tenfold spread from the lowest to the highest, which tells you the science has not yet converged on a single “correct” dose. What the research has done is give us a reasonable picture of what different dose levels appear to do.

The 2,000 FU per day mark shows up more frequently than any other single dose. It has been used across multiple randomized trials looking at blood clotting factors, blood pressure, and general cardiovascular health. If you see a nattokinase supplement on a shelf, chances are it contains somewhere around 2,000 FU per capsule, and that is not an accident. It reflects where the bulk of the human data sits.

Higher doses, in the 4,000 to 10,800 FU range, have been tested in trials specifically looking at lipid levels, atherosclerotic plaque progression, and more aggressive cardiovascular risk management. These are not fringe experiments. A study involving over a thousand participants used 10,800 FU per day for a full year. But these higher-dose studies tend to be fewer in number, and the question of whether more is reliably better remains open.

Effects on Clotting Factors at Moderate Doses

Nattokinase works primarily by breaking down fibrin, the protein mesh that forms the structural backbone of blood clots. It shares a strong structural similarity with plasmin, the body’s own clot-dissolving enzyme, and directly breaks apart fibrin strands rather than simply activating the body’s existing clot-clearing system.² This is the mechanism that has made it attractive as a cardiovascular supplement.

In one human trial, participants took two capsules of 2,000 FU each, twice daily, for a total of about 4,000 FU per day. After the treatment period, plasma fibrinogen dropped by roughly 9%, factor VII fell by about 14%, and factor VIII decreased by around 17%. All three of these are clotting-related proteins that, when elevated, raise the risk of cardiovascular disease.² Those are not dramatic drops, but they are meaningful in context. A 14% reduction in factor VII is the kind of shift that, sustained over years, could plausibly affect cardiovascular risk.

This matters for the dosing question because the study did not use the lowest dose on the spectrum. It used 4,000 FU per day, suggesting that people interested in measurable effects on clotting factors may need more than the minimum 2,000 FU dose found in many supplements. Whether 2,000 FU alone would produce similar changes is unclear from the available data.

What Happened at the Highest Tested Dose

The largest nattokinase trial to date enrolled 1,062 participants and gave them 10,800 FU per day for 12 months. The study was focused on atherosclerosis progression and blood lipid levels, not just clotting. After a year of daily supplementation at that dose, participants showed significant reductions in triglycerides, total cholesterol, and LDL cholesterol. HDL cholesterol, the kind you want higher, increased by about 15.8%.¹

Those are fairly robust lipid changes, especially the HDL boost. For context, a nearly 16% increase in HDL is in the same ballpark as what you might expect from regular aerobic exercise or moderate alcohol consumption. Whether nattokinase at lower doses, say 2,000 or 4,000 FU, would produce similar lipid benefits is genuinely unknown. The 10,800 FU dose is roughly five times what most supplement capsules contain, and nobody has published a head-to-head trial comparing low versus high doses for these particular outcomes.

This study stands out for its size and duration, but it also raises an important practical point. Taking 10,800 FU per day means swallowing five or more standard capsules every day for months. That is a commitment most casual supplement users are not making, and it moves nattokinase from the “one pill at breakfast” category into something closer to a therapeutic regimen.

Blood Pressure Effects

A randomized, double-blind, placebo-controlled trial conducted across multiple sites in North America tested nattokinase specifically for its effects on blood pressure. After eight weeks, the people taking nattokinase had a significantly lower average diastolic blood pressure compared to the placebo group: 84 mmHg versus 87 mmHg. That three-point difference was statistically significant. Systolic blood pressure also trended downward in the nattokinase group, but the difference from placebo did not reach statistical significance.³

A three-point drop in diastolic pressure is modest. It is not going to replace blood pressure medication for someone whose readings are dangerously high. But for someone whose blood pressure is mildly elevated and who is looking for lifestyle-level interventions, it is the kind of effect that adds up alongside other changes like reducing sodium or exercising more. The trial also found a reduction in von Willebrand factor, a protein involved in clotting and considered a cardiovascular risk marker, which fits the broader pattern of nattokinase affecting multiple parts of the blood-clotting and vascular system simultaneously.

Safety Profile Across Trials

One of the more reassuring findings across nattokinase research is the consistent absence of serious side effects. A systematic review and meta-analysis that pooled data from multiple randomized controlled trials found no notable adverse events reported among participants taking nattokinase or placebo.⁴ This held across different dosages and study durations.

That does not mean nattokinase is risk-free for everyone. Clinical trials screen out high-risk participants, including people on blood-thinning medications, which means the safety data reflects a relatively healthy population. The trials also run for months, not years, so long-term safety at higher doses like 10,800 FU per day remains less well-documented than short-term tolerability.

For most healthy adults taking standard supplement doses in the 2,000 to 4,000 FU range, the research suggests a favorable safety profile. Mild gastrointestinal symptoms are occasionally mentioned anecdotally, but they have not emerged as a consistent pattern in controlled studies.

When Nattokinase Becomes Dangerous

The single most alarming case report in the nattokinase literature involves a patient who had undergone aortic valve replacement with a mechanical prosthesis. He was prescribed warfarin, a blood thinner essential for preventing clots from forming on the artificial valve. About a year before he showed up at the hospital in crisis, he had stopped taking warfarin on his own and replaced it with 100 mg of nattokinase per day, a dose recommended by an alternative health publication. When surgeons reopened his chest, they found extensive fibrin and thrombus buildup on both sides of the mechanical valve discs.⁵

This case illustrates several things at once. First, nattokinase is not a substitute for prescription anticoagulants. Whatever its effects on clotting factors in healthy people, it cannot match the potency or predictability of drugs like warfarin in high-stakes situations. Second, it shows the real-world consequence of treating supplement marketing as equivalent to medical evidence. The patient made a reasonable-sounding decision based on a publication that was not equipped to give life-or-death pharmacological guidance.

Beyond the mechanical-valve scenario, anyone taking anticoagulant or antiplatelet medications should treat nattokinase with serious caution. Because it affects fibrin and multiple clotting factors, stacking it with prescription blood thinners could increase bleeding risk. If you are taking warfarin, heparin, aspirin, clopidogrel, or any of the newer direct oral anticoagulants, bringing up nattokinase with your doctor before trying it is not optional.

People scheduled for surgery present another risk category. Because nattokinase can thin the blood, many practitioners recommend stopping it at least two weeks before any planned surgical procedure, similar to the standard advice given for fish oil and high-dose vitamin E.

FU Versus Milligrams on the Label

Walk through a supplement aisle or browse an online retailer, and you will see nattokinase products labeled in wildly different ways. Some list the dose in milligrams, others in fibrinolytic units (FU), and some list both. This creates genuine confusion because the two numbers are not interchangeable in any simple way.

Fibrinolytic units measure the enzyme’s actual clot-dissolving activity, not its weight. A capsule containing 100 mg of nattokinase powder might deliver 2,000 FU or it might deliver considerably more or less, depending on the potency of the enzyme preparation, how it was fermented, and how it was processed. FU is the number that maps onto the clinical trial data. When a study says it used 2,000 FU per day, that refers to a specific level of fibrinolytic activity, regardless of how many milligrams of powder the capsule weighed.

This is why the case report of the man with the mechanical heart valve is especially instructive in a dosing context. He took 100 mg of nattokinase per day, but without knowing the FU count of that product, it is impossible to say how his dose compared to what was tested in clinical trials. He may have been taking far less fibrinolytic activity than even the lowest studied dose, or he may have been in the middle of the range but expecting an effect the enzyme simply cannot deliver in that clinical situation.

When shopping for nattokinase, the FU number is the one to pay attention to. If a label lists only milligrams and does not mention FU or fibrinolytic units anywhere, that is a red flag. It means either the manufacturer has not tested the enzyme activity or is not disclosing it, and you have no way to compare the product to what was actually studied.

What the Research Has Not Settled

Despite a reasonable body of evidence, there are real gaps. No regulatory agency has set an official recommended daily intake for nattokinase. The FDA treats it as a dietary supplement, which means it is not subject to the same pre-market approval process as drugs and there is no mandated dose on the label beyond whatever the manufacturer chooses.

Dose-response data, meaning research that directly compares different amounts of nattokinase in the same study to see which dose produces the best results, is essentially absent. We have individual studies at various doses, but nobody has run a large trial with arms at 2,000, 4,000, 6,000, and 10,800 FU to determine where the sweet spot is. The lipid improvements at 10,800 FU look promising, but it is possible that 4,000 FU gets you most of the way there. We simply do not know.

Long-term data beyond 12 months is thin. The largest trial ran for a year, which is respectable but does not tell you what happens with five or ten years of daily use. Given that the people most likely to take nattokinase are doing so as a long-term cardiovascular strategy, this is a meaningful blind spot.

There is also limited research on how nattokinase interacts with common medications beyond anticoagulants. The obvious blood-thinner interaction gets attention because it is the most dangerous, but nattokinase’s effects on clotting factors and blood pressure raise questions about interactions with antihypertensives, statins, and even common over-the-counter painkillers like ibuprofen that have their own mild antiplatelet effects. These questions have not been rigorously studied.

Timing, Food, and Absorption

Most clinical trials have administered nattokinase as oral capsules taken with or after meals, but few have specifically studied whether timing or food intake changes how much of the enzyme survives digestion and reaches the bloodstream. Nattokinase is a protein, which means the stomach’s acidic environment and digestive enzymes could theoretically break it down before it does anything useful. The fact that oral dosing produces measurable changes in clotting factors and blood pressure suggests enough of it survives to be active, but enteric-coated capsules, which resist stomach acid and dissolve later in the intestine, are sometimes marketed as superior for this reason.

Whether enteric coating actually matters has not been settled in comparative trials. Some manufacturers use it, some do not, and both types appear in studies that report positive results. If you are already taking a product without enteric coating and getting blood work that shows changes in the expected direction, there is no strong reason to switch. If you are starting fresh and choosing between two otherwise equivalent products, enteric coating is a plausible but unproven advantage.

Splitting the daily dose across two servings rather than taking it all at once is another common recommendation you will encounter. The trial that showed reductions in fibrinogen and clotting factors used a twice-daily dosing schedule, taking 2,000 FU in the morning and 2,000 FU later in the day.² Whether this matters more than total daily intake is unknown, but the logic is straightforward: enzymes are cleared from the body over hours, so spreading the dose could maintain more consistent activity throughout the day. For people taking 2,000 FU total, splitting is impractical since most capsules come in that size already. For those taking 4,000 FU or more, dividing into morning and evening doses is a reasonable approach that mirrors how some of the trials were actually conducted.